biomerica, inc. (www.biomerica.com) is a global biomedical company that develops, manufactures and markets advanced diagnostic products used at the point-of-care (in home and in physicians’ offices) and in hospital/clinical laboratories for the early detection of medical conditions and diseases. the company’s products are designed to enhance health and well-being, while reducing total healthcare costs. biomerica primarily focuses on products for gastrointestinal disease, diabetes and esoteric testing. the biomerica infoods® ibs product identifies patient specific foods that when removed may alleviate an individual's ibs symptoms. this patent pending diagnostic guided therapy is designed to allow for a patient specific guided dietary regimen to improve irritable bowel syndrome (ibs) outcomes. the point-of-care product is being developed to allow physicians to perform the test in-office using a finger stick blood sample while a clinical lab version of the product will be the first for wh
Company profile
Ticker
BMRA
Exchange
Website
CEO
Zackary S. Irani
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
NMS PHARMACEUTICALS INC, NUCLEAR MEDICAL SYSTEMS INC, NUCLEAR INSTRUMENTS INC
SEC CIK
Corporate docs
Subsidiaries
BioEurope GmbH • Biomerica de Mexico ...
IRS number
952645573
BMRA stock data
Latest filings (excl ownership)
10-Q
2024 Q3
Quarterly report
12 Apr 24
10-Q
2024 Q2
Quarterly report
16 Jan 24
8-K
Submission of Matters to a Vote of Security Holders
11 Dec 23
10-Q
2024 Q1
Quarterly report
12 Oct 23
EFFECT
Notice of effectiveness
2 Oct 23
CORRESP
Correspondence with SEC
29 Sep 23
UPLOAD
Letter from SEC
29 Sep 23
S-3
Shelf registration
27 Sep 23
DEF 14A
Definitive proxy
27 Sep 23
8-K
Regulation FD Disclosure
19 Sep 23
Latest ownership filings
SC 13G/A
Granahan Investment Management, LLC
14 Feb 24
SC 13G
WASATCH ADVISORS LP
9 Feb 24
4
Catherine Coste
14 Dec 23
4
DAVID MOATAZEDI
14 Dec 23
4
John P. Kenny
14 Dec 23
4
Jane Emerson
14 Dec 23
4
Gary Lu
14 Dec 23
4
ALLEN BARBIERI
14 Dec 23
4
Zackary S. Irani
14 Dec 23
4
DAVID MOATAZEDI
11 Dec 23
Financial summary
Quarter (USD) | Nov 23 | Aug 23 | May 23 | Feb 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | May 23 | May 22 | May 21 | May 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 7.13 mm | 7.13 mm | 7.13 mm | 7.13 mm | 7.13 mm | 7.13 mm |
Cash burn (monthly) | 284.67 k | (no burn) | 536.00 k | 527.25 k | 280.67 k | 433.67 k |
Cash used (since last report) | 1.36 mm | n/a | 2.57 mm | 2.53 mm | 1.34 mm | 2.08 mm |
Cash remaining | 5.77 mm | n/a | 4.57 mm | 4.61 mm | 5.79 mm | 5.06 mm |
Runway (months of cash) | 20.3 | n/a | 8.5 | 8.7 | 20.6 | 11.7 |
Institutional ownership, Q2 2023
29.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 34 |
Opened positions | 3 |
Closed positions | 4 |
Increased positions | 6 |
Reduced positions | 12 |
13F shares | Current |
---|---|
Total value | 5.80 bn |
Total shares | 4.92 mm |
Total puts | 100.00 |
Total calls | 700.00 |
Total put/call ratio | 0.1 |
Largest owners | Shares | Value |
---|---|---|
Granahan Investment Management | 1.14 mm | $1.56 bn |
Wasatch Advisors | 953.26 k | $1.30 bn |
Palm Management | 571.43 k | $1.56 mm |
Vanguard | 569.96 k | $775.15 mm |
Potomac Capital Management | 402.92 k | $547.97 mm |
Boothbay Fund Management | 294.38 k | $400.36 mm |
Russell Investments | 181.69 k | $247.09 mm |
BLK Blackrock | 158.26 k | $215.23 mm |
Geode Capital Management | 128.36 k | $174.56 mm |
Point72 Asset Management | 75.00 k | $102.00 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
13 Dec 23 | Catherine Coste | NQSO Common Stock | Grant | Acquire A | No | No | 1.01 | 75,000 | 75.75 k | 75,000 |
13 Dec 23 | Moatazedi David | NQSO Common Stock | Grant | Acquire A | No | No | 1.01 | 75,000 | 75.75 k | 75,000 |
13 Dec 23 | Kenny John P. | NQSO Common Stock | Grant | Acquire A | No | No | 1.01 | 75,000 | 75.75 k | 75,000 |
13 Dec 23 | Jane Emerson | NQSO Common Stock | Grant | Acquire A | No | No | 1.01 | 75,000 | 75.75 k | 75,000 |
13 Dec 23 | Gary Lu | NQSO Common Stock | Grant | Acquire A | No | No | 1.01 | 155,000 | 156.55 k | 155,000 |
News
12 Health Care Stocks Moving In Monday's Pre-Market Session
15 Apr 24
Biomerica Advances IBS Treatment with inFoods Product, Expands Physician Network Nationwide
15 Apr 24
Reported Late Friday, Biomerica Q3 EPS $(0.11) Up From $(0.12) YoY, Sales $1.02M Down From $1.11M YoY
15 Apr 24
Biomerica Received Decision Grant European Patent Number EP3497447 Titled "COMPOSITIONS, DEVICES, AND METHODS OF DEPRESSION SENSITIVITY TESTING"
11 Apr 24
12 Health Care Stocks Moving In Friday's After-Market Session
1 Mar 24
Press releases
Biomerica provides update on inFoods® IBS expansion
15 Apr 24
Biomerica Reports Third Quarter 2024 Financial Results
12 Apr 24
Biomerica InFoods IBS Data to be Presented at the Upcoming Digestive Disease Week (DDW) 2024 Conference
28 Mar 24
Diagnostics Industry Leader Gary Huff Appointed to Biomerica Strategic Advisory Board
21 Feb 24